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Abstract
Background: The COVID-19 pandemic and pandemic response created novel challenges for abortion 
services. Canada was uniquely positioned to transition to telemedicine because internationally 
common restrictions on abortion medication were removed before the pandemic.
Objective: We sought to characterize the experiences of abortion health care professionals in Canada 
during the COVID-19 pandemic and the impact of the pandemic response on abortion services.
Methods: We conducted a sequential mixed methods study between July 2020 and January 2021. 
We invited physicians, nurse practitioners and administrators to participate in a cross-sectional 
survey containing an open-ended question about the impact of the pandemic response on abortion 
care. We employed an inductive codebook thematic analysis, which informed the development of 
a second, primarily quantitative survey.
Results: Our initial survey had 307 respondents and our second had 78. Fifty-three percent were family 
physicians. Our first survey found respondents considered abortion access essential. We identified 
three key topicss: access to abortion care was often maintained despite pandemic-related challenges 
(e.g. difficulty obtaining tests, additional costs); change of practice to low-touch medication abortion 
care and provider perceptions of patient experience, including shifting demand, telemedicine acceptability 
and increased rural access. The second survey indicated uptake of telemedicine medication abortion 
among 89% of participants except in Quebec, where regulations meant procedures were nearly 
exclusively surgical. Restrictions did not delay care according to 76% of participants.
Conclusions: Canadian health care professionals report their facilities deemed abortion an 
essential service. Provinces and territories, except Quebec, described a robust pandemic transition 
to telemedicine to ensure access to services.
Podcast: An accompanying podcast is available in the Supplementary Data, in which the authors 
Dr Madeleine Ennis and Kate Wahl discuss their research on how family planning care and access 
to abortion services have changed during the COVID-19 pandemic.
Family Practice, 2021, i30–i36
https://doi.org/10.1093/fampra/cmab083
Lay Summary
Access to abortion care was challenged by the response to COVID-19. Canada had fewer restrictions 
on medical abortion than many other countries when the pandemic began. The goal of this study 
was to describe the experiences of health care practitioners providing abortion in Canada and 
the impact of the pandemic and the pandemic response measures on abortion services. We 
conducted two surveys of physicians, nurse practitioners and administrators between July 2020 
and January 2021. Most of the health care practitioners who participated reported that medical and 
surgical abortion care were essential and that, except in the province of Quebec, there was a rapid 
transition to virtual telemedicine care for first trimester abortions. Several practitioners said that 
virtual care made abortion more accessible. Other practitioners reported that it was challenging 
to order certain tests, access operating room facilities or make referrals for late second trimester 
cases. Practitioners felt that patients had strong fears about COVID-19 exposure and reported that 
limited contraception access was increasingly a reason for seeking abortion care. The results of 
the study suggested that abortion was considered essential and that the pandemic instigated a 
transition to virtual care in all provinces and territories except Quebec.
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Background
Access to essential, safe and comprehensive abortion care was jeop-
ardized by the global response to the COVID-19 pandemic in early 
2020. Restrictive measures designed to limit the spread of the virus, 
including those on nonessential travel and medical care, affected ac-
cess to reproductive and sexual health care (1). Legal and regulatory 
responses to this challenge were often regressive in international jur-
isdictions where abortion access was already limited (2–5). In other 
jurisdictions, progressive responses focussed on preserving access 
through telemedicine for early medical abortion (MA) care, since 
this minimized clinical points of contact and decreased the risk of 
COVID-19 exposure. For example, the UK, France, Australia and 
New Zealand temporarily allowed telemedicine for early MA, re-
moved requirements for routine screening ultrasounds and labora-
tory testing and increased gestational age limits for early MA to 
10–13 weeks of gestation (6–8).
Canada was uniquely positioned to transform MA care in-
sofar as several of these requirements regarding MA (mandatory 
screening ultrasound, physician dispensing of mifepristone) were re-
moved prior to the pandemic (9–11). The Society of Obstetricians 
and Gynaecologists of Canada (SOGC) also clearly stated at the be-
ginning of the pandemic that abortion care is an essential service, 
and access needed to be maintained (12,13). Abortion care is gov-
erned in Canada in the same way as any other reproductive health 
service, and is not regulated by criminal law. The decision to have an 
abortion is solely between a pregnant person and their health care 
provider and is not restricted by indication (e.g. foetal anomaly) or 
gestational age (9). By 2020, many primary care providers in Canada 
had incorporated first trimester MA into their clinical practices. An 
exception exists in the province of Quebec, which uniquely main-
tained restrictions that effectively limited MA care, and promoted 
surgical services (14,15). Barriers to providing MA care in Quebec 
include restrictive provincial medical licensing body policies, re-
strictive facility approaches with perceived vested interests in 
preserving surgical provision, lack of inter-professional support and 
general professional uncertainty about the regulations (14).
A growing body of evidence points to the safety and acceptability 
of low- or no-touch telemedicine abortion. An analysis of more than 
52 000 MA in the UK showed that the telemedicine‐hybrid model 
for care adopted in response to the pandemic was as effective, safe, 
acceptable and more accessible than conventional care provided in 
the first 3 months of 2020 (16). These findings align with other re-
search showing that home-based and telemedicine first trimester MA 
are safe with high rates of efficacy and acceptability (17,18). Existing 
research in several high-income nations also suggests providers may 
be interested in maintaining the liberalized practice changes imple-
mented since the beginning of the COVID-19 pandemic (19,20). 
However, more research is required to assess the sustainability of 
these regulatory changes. Turning to Canada, the impact of the 
COVID-19 pandemic and pandemic conditions on abortion care is 
unknown.
Therefore, our objective was to characterize the experiences of 
health care practitioners on the impact of COVID-19 and pandemic 
response measures on abortion care in Canada, with a focus on ac-
cess, telemedicine and early MA provision.
Methods
We conducted an exploratory sequential mixed methods study that 
involved the collection and analysis of qualitative data from our 
2019 Canadian Abortion Provider Survey (21) which, in turn, in-
formed the development of a second primarily quantitative survey. 
Key Messages
• Access to abortion care could potentially be jeopardized by the COVID-19 response.
• Unique regulations enabled Canada to deliver virtual abortion through primary care.
• Evidence-based virtual abortion services may increase access to care.
• Regulatory factors influence jurisdictions’ abilities to deliver care.
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We adapted the Standards for Reporting Qualitative Research 
Checklist for a mixed-methods approach (22). We conducted this 
second survey to further understand and quantify factors identified 
in the first survey through a refined set of questions and in response 
to a request from federal regulatory stakeholders.
Survey 1: The Canadian Abortion Provider Survey
Data collection
Between July and December 2020, we conducted a self-administered, 
anonymized, cross-sectional survey of Canadian physicians, nurse 
practitioners and administrators who provided first, second or third 
trimester medical or surgical abortion provision in 2019 (21). The 
University of British Columbia Children’s and Women’s Hospital 
Research Ethics Board approved the survey (UBC-CW REB, H18-
03303). It was available in English and French on the Research 
Electronic Data Capture (REDCap) platform, and included a con-
sent form, as well as sections on demographics, clinical character-
istics of abortion care and stigma experienced by providers. We 
distributed the survey through health care professional networks, 
using a modified Dillman technique to maximize participation (23). 
We included a non-mandatory, open-ended question: ‘What impacts 
has Covid-19 had on your individual abortion practice and/or access 
to abortion in your province?’
Data analysis
ME, KW and KK conducted a codebook thematic analysis (24) of 
open-ended responses following an inductive approach. We each 
read the same 50 responses to familiarize ourselves with the data and 
then independently coded these responses. Next, we compared our 
analyses, and agreed on an initial set of codes and descriptions for 
the codebook. We then divided the full set of responses and coded 
these independently. Subsequently, we refined existing codes and de-
scriptions and agreed on new codes that were identified in the inde-
pendent analysis. We used the revised codebook in a final analysis 
of the data, after which we organized the codes into topics related 
to the research question (see Supplementary Data). In the context 
of this low-inference approach, contemporaneous team discussions 
helped identify how personal attributes, qualifications and assump-
tions interacted with the data and analysis.
Survey 2: Community of Practice Survey
We used the identified topics in the Survey 1 analysis to develop a 
second survey to assess the impact of the pandemic on the provi-
sion of Canadian abortion services. From December 2020 to January 
2021, we conducted the survey (UBC-CW REB, H16-01006), 
which included a consent form and questions assessing brief demo-
graphics, monthly MA volume from January to September 2020, 
previous experience providing MA via telemedicine, and the impact 
of the COVID-19 pandemic on the provision of abortion services 
(see Supplementary Data). We excluded respondents practicing in 
Quebec from analysis of MA-related questions, as restrictive med-
ical policies sustained providers’ preference for surgical abortion and 
provincial/administrative inertia limit access to MA (15,25). This 
survey was available in English and French and we invited mem-
bers of the Canadian Abortion Providers Support—Communauté de 
pratique canadienne sur l’avortement network (a national commu-
nity of practice to support mifepristone abortion practice) via regis-
tered email (10,26). As Survey 1 also recruited through this platform, 
there may have been overlap in participants. We generated summary 




A total of 307 participants responded to the pandemic-related open-
ended question. Their demographics are provided in Table 1. All 
participants confirmed they completed the survey only once, were 
no longer in training, and independently provided abortion care in 
Canada. Twelve participants indicated they were both clinicians and 
administrators.
We identified three common topics related to the impact of the 
COVID-19 pandemic on abortion care in Canada: access to care, 
change in practice and perceptions of the patient experience.
Access to abortion care
Many abortion providers indicated that the pandemic did not affect 
their ability to provide access because they or their province con-
sidered abortion care essential. One family physician from Alberta 
(ID 110) said, ‘In our community, we have considered abortion and 
contraceptive care to be an essential service and have made sure ac-
cess continued throughout COVID restrictions’. Several participants 
Table 1. Demographics of respondents to the COVID-19 open-
ended question in the Canadian Abortion Provider Survey con-
ducted in 2020 (n = 307)
Provincea, n






 Prince Edward Island and  
Newfoundland and Labrador
7
 New Brunswick 11







 Nurse practitioner 18
Specialtyc, n
 Family physician 163
 General OB/GYN 69
 OB/GYN with MFM subspecialization 25
 Other 5
Provision, n
 First trimester MA 212
 First trimester surgical abortion 114
 Second trimester surgical abortion 55
 Second trimester MA 55
 Third trimester MA 35





MFM, maternal–foetal medicine; OB/GYN, obstetrician–gynaecologists.
aSome provinces and territories were combined for confidentiality pur-
poses.
bProfession of clinicians; does not include administrators.
cSpeciality of physicians; does not include administrators or nurse practi-
tioners.
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described an increase in access to care during the pandemic, ‘We 
have found that many patients throughout the province have util-
ized our service due to an increase in accessibility that accompanies 
telemedicine, and we are hopeful to continue to offer this care. 
However, we are also aware that for patients who do not have access 
to a phone/internet, telemedicine is not accessible’ (administrator, 
Ontario, ID 27). Some participants providing in-person care noted 
that reduced clinic hours had affected access. Barriers to timely care 
included challenges accessing tests, for example ‘Difficulty getting 
ultrasounds, labs done (less staff for both for booking/performing) 
[and] difficulty communicating with other offices as people are gen-
erally more busy and understaffed’ (administrator, British Columbia, 
ID 272). Some abortion providers reported fewer requests for abor-
tion (both from patients and through referrals) and a number of 
surgical providers indicated that access to operating theatres was 
limited. Finally, several participants perceived that their patients had 
experienced limited access to contraception care.
Change of practice
The majority of respondents reported a change from in clinic to 
low- or no-touch care with virtual components. The degree of this 
change varied from ‘I have shifted the first or subsequent visits to 
telephone visits but usually require in person assessment at least 
once’ (family physician, British Columbia, ID 6) to ‘I have offered 
entirely telehealth abortion care for early first trimester pregnan-
cies. Minimized investigations—bloodwork initially and clinically 
history of heavy bleed and resumption of menses as confirmation’ 
(family physician, British Columbia, ID 196). Some first trimester 
MA providers prescribed a second dose of misoprostol routinely. 
Others indicated increasing gestational age limits for second tri-
mester in hospital abortions/labour inductions when patients 
could not be referred elsewhere. An obstetrician–gynaecologist 
(British Columbia, ID 164) described, ‘We are providing medical 
abortion care to women ≥25 weeks gestation with fetal anomalies/
genetic anomalies that we would have normally referred to a US 
centre’.
Many participants described positive experiences, for example 
‘We have moved quite seamlessly to no-touch medical abortion 
services and this has been quite successful and rewarding’ (nurse 
practitioner, Ontario, ID 498). Participants who did experience 
difficulties with the transition to low- or no-touch care identified 
resource issues, including increased costs to adhere to infection pre-
vention and control measures as well as staffing shortages resulting 
from secondment to other roles, new childcare demands or limited 
ability to travel between clinics. Depending on jurisdiction, billing 
contributed to or mitigated costs. In Alberta, a family physician (ID 
29) described ‘the telephone visit code really doesn’t compensate for 
the length of time spent counselling pre and post abortion’ whereas 
in Nova Scotia, a family physician (ID 284) highlighted ‘Provincial 
fee to provide medical care via telephone has been helpful’.
Perceptions of the patient experience
Many respondents commented on patient behaviour and experi-
ences. A common observation was that demand for care decreased 
in the early months of the pandemic, and providers hypothesized 
that this was due to decreased frequency of intercourse as well as 
fears about contracting COVID-19, as a family physician from the 
Territories (ID 691) described, ‘Patients are more reluctant to travel 
out of territory to access abortion care beyond the first trimester be-
cause they are terrified of the virus, and do not want to self-isolate at 
hotel hubs for 14 days before re-entering the territory’. Participants 
shared anecdotes about patients who presented for care at a later 
gestational age or continued with pregnancy because of fears about 
contracting COVID-19 or, in one case, because a patient tested posi-
tive for the virus and was unable to travel for care. Participants gen-
erally reported that patients were more likely to request MA care 
over surgical, felt that patients were anxious, and noted that at most 
clinics, support people were not permitted to attend appointments.
Survey 2 results
The survey was completed by 78 respondents. Their demographics 
are provided in Table 2. The number of MAs provided monthly by 
respondents increased slightly in April 2020, with the mean volume 
ranging from 4.9 to 5.8 prior to April 2020, and ranging from 6.1 
to 7.3 after April 2020. Since March 2020, 91% of respondents had 
provided medical or surgical abortion services. We did not iden-
tify any new codes in the qualitative analysis of the open-ended 
questions.
Volume
Among respondents who reported providing MA during the pan-
demic (n = 61), 52.5% reported that the number of MAs increased, 
41% reported that the number of MAs did not change and 6.5% 
reported a decrease in the number of MA.
Timely access
Among respondents who have provided medical and/or surgical 
abortion during the pandemic (n = 63), 76% reported that their pa-
tients did not experience delays in care due to restrictive measures.
Telemedicine
Among respondents who have provided first trimester MA virtually 
(n = 55), 83.6% had no experience providing MA virtually before 
the pandemic. However, 88.9% responded that they had provided 
MA virtually since the pandemic. The majority of respondents pro-
viding first trimester MA virtually offered pre-abortion consultation/
counselling, prescription and follow-up virtually (90.9%, 85.5% 
and 90.9%, respectively). Forty-nine percent responded that they 
provided virtual emergency care.
Table 2. Demographics of the Community of Practice Survey re-
spondents (2020–21; n = 78)
Provincea, n
 Western Provincesb 32
 Ontario 29
 Quebec 10
 Maritime Provinces and Territoriesc 7
Role, n
 Physicians 65
 Nurse Practitioners 6




aSome provinces and territories were combined for confidentiality purposes.
bIncluded participants from British Columbia, Alberta, Saskatchewan and 
Manitoba.
cIncluded participants from New Brunswick, Newfoundland and Labrador, 
Nova Scotia, Northwest Territories and Yukon.
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Furthermore, respondents who provided first trimester MA virtu-
ally during the pandemic (n = 48) were asked about situations where 
they required testing, summarized in Table 3.
Finally, respondents who have provided medical and/or surgical 
abortion during the pandemic (n = 63) were asked about difficulties 
mentioned by patients in accessing abortion services, summarized 
in Table 4. The most common mentioned difficulty was fear of ex-
posure to COVID-19 in public locations.
Discussion
This study, which assesses changes in access to Canadian abortion 
services since the COVID-19 pandemic, is novel, timely, and has the 
potential for rapid impact on policy. Most abortion providers in 
most Canadian provinces and territories reported a seamless switch 
to providing a higher proportion of MA compared with surgical 
abortion, and an increase in telemedicine. Though several difficulties 
were reported most strikingly in Quebec, this transition was enabled 
by the support and pandemic guidelines of SOGC (12).
Our findings indicate that the availability of abortion care 
was maintained and a rapid transition to telemedicine MA was 
experienced, in provinces and territories except for Quebec. This 
contrasts to the experiences reported in some jurisdictions inter-
nationally (1,4,5,19,27–29). For example, a rapid response 
survey of independent abortion clinics in the USA showed that, 
51% of clinics, clinicians or staff had been unable to work be-
cause of the pandemic or public health response (27). Across many 
European nations, the USA and in other jurisdictions (3,5), legal 
and regulatory restrictions on abortion care have been a barrier 
to following evidence-based guidelines for pandemic abortion care 
(2,27). In contrast, the Canadian transition to pandemic abor-
tion care, similar to that reported by Gibelin in France (19) and 
Aiken in the UK (16), was quickly implemented and deemed es-
sential. Rapid transition to telemedicine first trimester MA was 
likely facilitated by the removal of restrictions by the federal drug 
regulator Health Canada in 2019, and hindered by the ongoing 
restrictive regulations in Quebec (14,15,30). The supportive regu-
latory framework—which did not prescribe testing—enabled pro-
viders to adopt evidence-based guidelines for abortion care during 
pandemics and periods of social disruption beginning in April 
2020 (12,13), including reductions in the indications to order pre-
procedural ultrasound, bHCG and Rh factor tests.
The results of this study may have important implications in jur-
isdictions seeking to advance reproductive health during and after 
the COVID-19 pandemic response. Our findings suggest that low- 
or no-touch MA provided in primary care may increase geographic 
equity in access to safe care. This approach has the potential to ad-
dress barriers to in-clinic care, such as the burden among patients 
who care for others. Our results indicate that consideration of pa-
tient economic status (results of Survey 2) and access to communi-
cation technology (results of Surveys 1 and 2)  may be important 
for optimizing equitable access to abortion. Finally, a comprehen-
sive approach to reproductive health care is vital, since considering 
contraception care as nonessential or implementing policy restricting 
dispensation (31), may have negative consequences even where ac-
cess to abortion care is preserved.
Table 3. Requirements for clinical tests by Canadian medical abortion providers during the COVID-19 pandemic (2020–21; n = 48)a
Always, n (%) As indicated, n (%) Never, n (%) Not applicable, n (%)
Ultrasound 9 (18.8) 39 (81.2) 0 (0) 0 (0)
Rh testing 17 (35.4) 20 (41.7) 10 (20.8) <5 
Serum bHCG 28 (59.6) 18 (38.3) <5 0 (0)
Haemoglobin 25 (55.6) 16 (35.6) <5 0 (0)
STI testing 18 (37.5) 25 (52.1) 5 (10.4) 0 (0)
STI, sexually transmitted infections. <5 is used to ensure confidentiality of participants.
aDoes not include participants from Quebec; only includes participants who provided first trimester medical abortion care during the COVID-19 pandemic.
Table 4. Difficulties for patients to access services during the COVID-19 pandemic (2020–21) as reported by Canadian abortion providers 
(n = 63)
Number of providers who responded that their patients 
mentioned experiencing difficulty, n (%)
Difficulty obtaining information on abortion services 16 (25.4)
Delay in getting a referral for abortion care 16 (25.4)
Social distancing 8 (12.7)
Lockdowns or decrease transportation between regions 12 (19.0)
Interruption of local transportation 11 (17.5)
Increase of restrictive legal measures against abortion 0 (0)
Re-organization of medical services 11 (17.5)
Medical leaves of health professionals <5
Change in opening/closing hours of shops, clinics or community organizations 13 (20.6)
Fear of getting COVID in public locations 28 (44.4)
Being diagnosed with a positive test for COVID-19 9 (14.3)
Lack of privacy for medical abortion at home <5
Intimate partner violence 10 (15.9)
Loss of income 14 (22.2)
Difficulty related to technology 15 (23.8)
<5 is used to ensure confidentiality of participants.
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The experiences of health professionals providing abortion care 
in Canada during the COVID-19 pandemic illustrates opportun-
ities for evidence-based provision of low- and no-touch first tri-
mester MA in primary care and providing advanced gestational age 
abortions closer to the patient’s home rather than referring them 
elsewhere including to the USA. Strengths of the study include the 
large national sample and the integration of qualitative and quanti-
tative data, which provided a rich contextual understanding of the 
Canadian transition to pandemic abortion care from a front-line 
perspective. Interpretation of the results may be limited by the po-
tential for overlap in participants between the surveys. A  further 
limitation is that the patient experience of pandemic abortion care 
is described from the perspective of health care professionals. The 
second survey had a smaller sample size than the first. We sought 
understanding to assist interpretation of our qualitative findings and 
thus fielded the quantitative questions using a limited recruitment 
method through one network, that was open to respondents for 
2 months. While beyond the scope of this study, future research led 
by our team will investigate patient experiences, including percep-
tions of telemedicine abortion care and safety of low- and no-touch 
abortion care in Canada. Further investigation into provincial/ter-
ritorial differences in care and access, including factors explaining 
the persistence in restrictive policies on first trimester MA care in 
Quebec, would allow for more targeted knowledge translation and 
policy development plans.
In the 10  months following the outbreak of the COVID-19 
pandemic, Canadian abortion providers from all provinces except 
Quebec, reported quickly and easily transitioning to the provision 
of virtual MA. This transition was influenced by previous federal 
removal of regulatory restrictions, and by the rapidly developed 
and disseminated national guidelines on virtual abortion care. Our 
results highlight opportunities to optimize equitable abortion care 
both in Canada and internationally.
Supplementary material
Supplementary material is available at Family Practice online.
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